Post the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...

“It is business as usual and it will be done by us. They are taking this to increase their bandwidth and also for us to develop the revenue...

Market capitalisation of Suven Pharma, as on Friday, was ₹12,682.43 crore. ET was the first to report on the sale on December 23. Advent is...

Announcement expected as early as Monday morning. Open offer if fully subscribed to could make it a $1 bn deal

Promoters Venkateswarlu Jasti and his family split Suven Life Sciences in FY20, turning the CRAMS business into a separately listed company...

The 9405 sq. ft property was purchased by Bhagwati Devi Baldwa, a director with a Hyderabad-based firm. The residential property was earlie...

New investor to become controlling shareholder in likely Rs 6,500 cr deal; due diligence begins

The analyst suggested a stoploss at Rs 305.

Buy Suven Life Sciences Ltd. at a price target of Rs 312.0 and a stoploss at Rs 280 from entry point.

Buy Suven Life Sciences at a price target of Rs 250 and a stop loss at Rs 202 from entry point.

Buy Suven Life Sciences at a price target of Rs 205 and a stop loss at Rs 166 from entry point.

Buy Suven Life Sciences Ltd. at a price target of Rs 210.0 and a stop loss at Rs 189.0 from entry point